Teva, the Israeli generic drugs company, is to acquire Barr of the US in a $7.5bn deal that will sharply reinforce its position as the
largest seller of off-patent medicines.
Teva gains edge in generics with its $7.5bn Barr deal
By Andrew Jack in London
Published: July 19 2008 03:00 | Last updated: July 19 2008 03:00
You have viewed your allowance of free articles. If you wish to view more, click the button below.
